Nama's AI scorecard currently rates Incyte Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is INCY's P/E ratio?

Incyte trades at a trailing price-to-earnings ratio of 38.6.

When does INCY report earnings?

Incyte's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $2.01.

What is the INCY price target?

The median analyst price target from 24 analysts is $130.00, with a range of $86.00 – $157.00.

Is INCY Shariah compliant?

Nama's AAOIFI-style screen reads Incyte as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Incyte (INCY)

Healthcare · Biotechnology · NASDAQ

S&P 500

Incyte (INCY) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $24.39B, a trailing price-to-earnings ratio of 38.6 and a free-cash-flow yield of 5.5%. Over the most recent reported fiscal year, revenue grew 21.2% and free cash flow per share grew 493.1%. Nama's AI scorecard rates it Buy, 7.0 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 7.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +7.8% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-9.8%

How far the last close sits under the highest price of the past five years.

Market cap	$24.39B
Trailing P/E	38.6
Price / book	4.3
Price / sales	4.1
FCF yield	5.5%
Dividend yield	—
Gross margin	92.7%
Operating margin	11.7%
Net margin	6.7%
Revenue growth (YoY)	+21.2%
Revenue growth (3-yr annual)	+14.8%
EPS growth (YoY)	+414.4%
FCF/share growth (YoY)	+493.1%
Beta	0.7
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

INCY earnings

Next report: Feb 9, 2027 (Q4 2026, EPS estimate $2.01). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	-$3.60	-$3.87	+7.0%	$1.56B
Q2 2026	Jul 28, 2026	$3.09	$2.15	+43.7%	$1.67B
Q1 2026	Apr 28, 2026	$1.81	$1.34	+35.1%	$1.27B
Q4 2025	Feb 10, 2026	$1.80	$1.92	-6.2%	$1.51B

INCY analyst price target

Median target $130.00 from 24 analysts, ranging $86.00 – $157.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live INCY data on Nama Insights →

Recent Congressional trades

Incyte trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Rob Bresnahan	House	Sell	$1,001 - $15,000	May 31, 2025
Shelley M Capito	Senate	Sell	$1,001 - $15,000	—
Shelley M Capito	Senate	Buy	$1,001 - $15,000	—

INCY FAQ

Is INCY a buy?: Nama's AI scorecard currently rates Incyte Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is INCY's P/E ratio?: Incyte trades at a trailing price-to-earnings ratio of 38.6.
When does INCY report earnings?: Incyte's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $2.01.
What is the INCY price target?: The median analyst price target from 24 analysts is $130.00, with a range of $86.00 – $157.00.
Is INCY Shariah compliant?: Nama's AAOIFI-style screen reads Incyte as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.